


# Hyperbilirubinemia Pathway: ED Management

For use in patients ≤14 days old, gestational age ≥35 weeks, and concern for jaundice or elevated bilirubin



- Obtain heel stick fractionated bilirubin level per CIP 5 - 27: Policy Manager – MCN Healthcare
- Obtain birth history<sup>1</sup> and % below birth weight
- Review patient's risk factors for significant neurotoxicity<sup>2</sup>
- Continue to encourage feeding (breast milk, formula)

## EXCLUSION CRITERIA

- Concern for other associated illnesses: infection/sepsis, cardiac disease, metabolic disease

## BIRTH HISTORY<sup>1</sup>

- Maternal and infant blood type, RhD, DAT
- Gestational age
- Birth date and time
- Birth weight
- Delivery complications
- History of phototherapy during birth hospitalization
- Feeding history

## SIGNIFICANT NEUROTOXICITY RISK FACTORS<sup>2</sup> (Other than gestational age)

- Isoimmune hemolytic disease
  - Check Care Everywhere for maternal antibodies/baby's DAT at birth
- Other hemolytic disease (e.g. G6PD deficiency)
- Albumin < 3.0 g/dL (if known)
- Significant clinical instability in the previous 24 hours, sepsis

## ADDITIONAL LABS<sup>3</sup>

- Obtain DAT if maternal blood type is unknown/O/Rh negative, or antibody screen at delivery was positive
- CMP if ill-appearing/dehydrated
- Reticulocyte count and type and screen if hemolysis

## PHOTOTHERAPY<sup>4</sup>

- When indicated, start phototherapy as soon as possible. Use Biliblanket if available
- Assess need for escalation of care if TSB is within 2 mg/dL of exchange transfusion threshold based on chart 3\*(no neurotoxicity risk factors) or chart 4\*(neurotoxicity risk factors present).
- If escalation of care is indicated:
  - Phototherapy STAT
  - Consult NICU
  - CBC, CMP, DAT, type and crossmatch
  - IVF hydration

## RETURN TO ED IF PCP NOT AVAILABLE<sup>5</sup>

\*THESE VALUES MAY BE PLOTTED ON [BILITOOLO.ORG](http://BILITOOLO.ORG)


# Hyperbilirubinemia Pathway: ED Management

For use in patients  $\leq 14$  days old, gestational age  $\geq 35$  weeks, and concern for jaundice or elevated bilirubin


February 2025



## Phototherapy Thresholds: No Hyperbilirubinemia Neurotoxicity Risk Factors (other than gestational age)



## Phototherapy Thresholds: One or More Hyperbilirubinemia Neurotoxicity Risk Factors (other than gestational age)




\*THESE VALUES MAY BE PLOTTED ON [BILITOOLO.ORG](https://www.bilitool.org)


# Hyperbilirubinemia Pathway: ED Management

For use in patients  $\leq 14$  days old, gestational age  $\geq 35$  weeks, and concern for jaundice or elevated bilirubin

## Exchange Transfusion Thresholds: No Hyperbilirubinemia Neurotoxicity Risk Factors (other than gestational age)



## Exchange Transfusion Thresholds: One or More Hyperbilirubinemia Neurotoxicity Risk Factors (other than gestational age)



\*THESE VALUES MAY BE PLOTTED ON [BILTOOL.ORG](https://www.biltool.org)